The Zantac litigation continues to move forward in state court. The Zantac state court litigation will have a slightly more narrowed focus compared to the initial class action MDL in federal court. The Zantac litigation will focus more on specific types of cancer that have the strongest evidence linking them to NDMA and Zantac use.
This page is for parents looking to bring a WanaBana lawsuit on behalf of their child and their family for lead poisoning from this product.
Parents are angry and frustrated and want answers. This page provides answers for victims wondering what to do and how to seek settlement compensation. Our lawyers also provide the most recent information on the recall and the developments in the litigation, including the bankruptcy which may kill this litigation.
There is a new lawsuit involving the promotion and use of a dental device known as the Anterior Growth Guidance Appliance (AGGA). The lawsuit contends that the AGGA, which was marketed as a non-surgical solution for correcting dental, facial, and airway abnormalities, lacks scientific backing and has not been proven safe or effective for adult patients.
The core of the allegations centers on the assertion by the defendants that AGGA could induce substantial alterations in the adult nasomaxillary complex, including advancing the maxilla forward significantly, through mechanical force and bone growth stimulation.
Plaintiffs challenge these claims as unfounded and in direct conflict with established medical understanding, asserting that the device may, in fact, cause harm by displacing upper teeth from their sockets and leading to severe dental and skeletal issues.
As a result of the opioid addiction crisis, thousands of babies in the U.S. became addicted to opioids in utero and were born with Neonatal Abstinence Syndrome and suffered opioid withdrawal at birth. Parents of these children are now filing lawsuits against the opioid manufacturers. If your child was diagnosed with Neonatal Abstinence Syndrome or opioid withdrawal at birth, contact our national mass tort lawyers today to see if you qualify.
Over the past two decades, the number of opioid prescriptions has nearly quadrupled, fueling the ongoing opioid epidemic that has swept through our nation and brought devastation to countless families and communities. Recent estimates reveal that a baby born addicted to opioids emerges in the U.S. approximately every 19 minutes, with many newborns experiencing drug withdrawal symptoms and potential developmental issues daily.
The blame for this crisis often falls on drug manufacturers and distributors who knowingly played down the risks of opioid painkillers leading to physical dependency. Several pharmaceutical companies have faced repercussions for their deceptive and unlawful marketing of drugs like OxyContin, which, like other opiates, can serve as a gateway to heroin use. The consequences of Neonatal Abstinence Syndrome (NAS) can be profound, potentially resulting in lifelong complications and substantial medical costs that can place significant financial strain on families. You and your baby should not have to endure such traumatic circumstances.
This page discusses the link between AFFF firefighting foam and various types of cancer, which has led to thousands of AFFF lawsuits across the country.
If you have an AFFF cancer lawsuit and you want to understand your options, call us today for a free case evaluation at 800-553-8082 or contact us online.
Aqueous film-forming foam (“AFFF”) is generally known as firefighting foam and it has been used for decades to combat fires fueled by accelerants. AFFF contains high levels of chemicals called PFAS and recent research has shown that occupational exposure to PFAS can cause certain types of cancer. Kidney cancer is one of the diseases that has been scientifically linked to occupational exposure to AFFF firefighting foam.
This page will look at AFFF firefighting foam lawsuits involving kidney cancer and their potential settlement value.
Product liability lawsuits are being filed around the country, claiming that the popular baby formula Enfamil has caused premature babies to develop a severe gastrointestinal infection called necrotizing enterocolitis (NEC).
Our national mass tort firm is currently seeking potential Enfamil lawsuits against the formula manufacturer based on its failure to warn about the risks of NEC. You could receive significant financial compensation if you qualify for an infant formula NEC lawsuit and are successful.
Johnson & Johnson Consumer Inc. has been defending a series of class action lawsuits claiming that the company’s OGX line of shampoos and conditioners contains chemicals that cause hair loss. The lawsuits accuse J&J of marketing OGX hair products as afe and capable of repairing, nourishing, and reviving hair. According to the plaintiffs, however, these products contain chemicals such as formaldehyde and DMDM, which are known to be harmful and can cause hair loss.
This page is about lawsuits involving OGX shampoo. We provide you with numerous details here that our lawyers believe may be helpful to you, including the current status of the pending litigation. But our law firm is not handling these cases.
A growing number of lawsuits are being filed against social media companies like Facebook, Instagram, and Snapchat, alleging that teens suffered physical and mental injuries after becoming addicted to social media. This page will explain the eligibility criteria for bringing a social media addiction lawsuit and how our firm screens potential social media addiction cases.
Over the last few years, a wave of injury lawsuits have been filed against social media platforms like Instagram, Facebook, and others, alleging that teens became addicted to these platforms and suffered physical and mental damage as a result. The social media lawsuits are based on two primary allegations: (1) the social media companies knowingly designed their platforms to get teenagers addicted to using them, and (2) addiction to social media caused significant physical and mental harm to younger users.
Tasigna is a relatively new drug developed by Novartis for the treatment of leukemia. Not long after Tasigna was released in the U.S., evidence emerged indicating that Tasigna could cause a dangerous condition called atherosclerosis (narrowing of the blood arteries to the heart).
Plaintiffs’ lawyers claim that Novartis knew or should have known about this dangerous side-effect, but failed to include a warning in the prescribing information.
Users of Tasigna who suffered vascular damage from this undisclosed side-effect may be entitled to compensation for their injuries. Novartis has already been sued in a growing number of Tasigna lawsuits and a new “class-action” MDL has been created for consolidated handling of the Tasigna cases.
Lawsuit Information Center